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Beta2-Integrins and Their Roles in the Immune System
Members of the beta2-integrin family are expressed exclusively 
on leukocytes. The beta2-integrin family has four members, sharing a 
common beta-chain (the beta2- or CD18 integrin), but with different 
alpha chains (CD11a/CD11b/CD11c/CD11d) that convey the ligand 
specificity and function of each integrin subtype [1]. Beta2-integrins 
mediate cell adhesion and signalling in immune cells (Figure 1) and are 
of pivotal importance for immune system function in vivo.
LFA-1 (CD11a/CD18; alphaLbeta2-integrin) is expressed on all 
leukocytes andbinds to members of the ICAM (intercellular adhesion 
molecule) family. LFA-1 mediates the firm adhesion of leukocytes to 
endothelial cells surrounding blood vessels, which is necessary for 
leukocyte extravasation at inflammatory sites. Selectin binding and 
inflammatory signals (such as chemokines) stimulate the increase in 
LFA-1 affinity necessary for firm adhesion to ICAM-ligands. LFA-1 
expressed on T cells also binds to ICAM -1 on antigen presenting cells 
at the immune synapse, thereby strengthening the interaction between 
the cells and optimising subsequent signalling and T-cell activation 
[1,2].
In contrast to LFA-1, which is found on all leukocytes, Mac-1 
(CD11b/CD18; alphaMbeta2-integrin) is mainly expressed on myeloid 
cells (such as neutrophils, monocytes, macrophages and myeloid 
dendritic cells). Mac-1binds to a wide variety of ligands including 
ICAM-1 and complement component iC3b; Mac-1 is also called 
complement receptor 3(CR3). Through binding to iC3b, the Mac-
1 integrin mediates phagocytosis of complement opsonised bodies, 
including pathogens, apoptotic cells and immune complexes [3]. 
Mac-1 binding to ICAM-1 is important for neutrophil extravasation 
at inflammatory sites [4]. Recently, it has become apparent that Mac-
1 is also an important negative regulator of leukocyte function. For 
example, Mac-1 restricts dendritic cell (DC) maturation and function 
[5] and DC-induced T cell activation [6]. Mac-1 also plays a role in oral 
tolerance by restricting Th17 cell differentiation [7]. In macrophages, 
Mac-1 has been reported to restrict Toll-like receptor (TLR) signalling. 
In these cells, Mac-1 induces Src/Syk signalling, which results in 
degradation of TLR signalling adaptors MyD88 and TRIF [8]. In 
addition, Mac-1 has also been implicated in limitingmacrophage 
inflammatory responses through the induction of signalling inhibitors 
such as SOCS3 and A20, as well as the anti-inflammatory cytokine IL-
10 [9]. Thus, Mac-1 has an important role in limiting pro-inflammatory 
responses in addition to its critical roles as a complement receptor and 
in extravasation.
Complement receptor 4 (CR4; CD11c/CD18) is very similar to 
Mac-1, and these two beta2-integrin family members appears to have 
overlapping functions. Like Mac-1, CD11c/CD18 also binds iC3b and 
mediates phagocytosis of iC3b-coated particles, and immune complex 
clearance. This receptor also binds fibrinogen and ICAM ligands and 
may play a role in leukocyte adhesion and migration [10]. It appears to 
be necessary for protection from systemic Candida-albicans infections 
[11].
Relatively little known is known about CD11d/CD18 (alphaMbeta2), 
the fourth and most recently discovered beta2-integrin, though a few 
recent studies have shed some light onto the potential functions of this 
integrin [12,13].
Leukocyte Adhesion Deficiency (LAD)
A loss of beta2-integrin expression or function is associated with 
the genetic syndrome Leukocyte Adhesion Deficiency (LAD). LAD 
is a group of primary immunodeficiency disorders characterised by 
persistent infections caused by an inability of immune cells to adhere 
to the endothelium and migrate to infected tissue [14]. LAD can be 
divided into three different subtypes (LAD-I-III), depending on the 
causative mutation(s) [15]. 
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Abstract
Integrins are heterodimeric transmembrane receptors that mediate cell-cell and cell-extracellular matrix 
interactions. Beta2-integrins are expressed exclusively in leukocytes and mediate many important functions in the 
immune system. Beta2-integrin genes are important in the pathologies of several diseases and genetic syndromes. 
These include Leukocyte Adhesion Deficiency (LAD) and Systemic Lupus Erythematosus (SLE), disorders which 
lie at opposite ends of the spectrum of immunological diseases. In LAD-I and LAD-III syndromes, beta2-integrin 
expression or function is reduced or absent. In SLE, genetic variants of the ITGAM gene, which encodes for the alpha 
M/CD11b chain of the beta2-integrin Mac-1,are associated with SLE development. In this mini review we summarise 
current knowledge regarding the involvement of beta2-integrins in LAD and SLE. Interestingly, dysfunctional beta2-
integrins have been linked to both disorders, shedding light on the diverse roles of these receptors in the immune 
system.
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LAD-I
LAD-I can be caused by somatic mutations in the promoter region 
of the beta2-integrin gene resulting in reduced or no expression of 
beta2-integrin protein. Alternatively, mutations within the coding 
region of the beta2-integrin gene give rise to a truncated or non-
functional beta2-integrin subunit. Over 200 separate mutations have 
been identified that result in reduced expression of the beta2-integrin 
protein. The severity of the disorder varies depending on the level of 
remaining beta2-integrins on the cell surface [16].
Since beta2-integrins are crucial for leukocyte function, particularly 
for leukocyte migration into sites of infection, LAD-I patients suffer 
from recurrent bacterial infections, fungal infections, delayed wound 
healing, leucocytosis and periodontitis. Because neutrophils don’t 
express high levels of other integrin subfamilies that could compensate 
for the lack of expression of beta2-integrin, their migration into sites of 
infection and functions are particularly affected by this disorder. 
Beta2-integrin knockout mice display splenomegaly, increased 
circulating neutrophil numbers and are susceptible to infections. The 
phenotype of these mice resembles that of human LAD-I patients, and 
they have been useful for the elucidation of beta2-integrin function 
in different immune cells and immune processes in vivo [17-20]. The 
phenotype of leukocytes in LAD-I and beta2-integrin knockout mice 
reveal the crucial importance of beta2-integrins (probably LFA-1 in 
particular) in mediating firm adhesion of neutrophils to endothelial 
cells under shear flow conditions, and therefore in immune defence 
against bacteria and fungi in particular [21]. 
LAD-II
LAD-II is much rarer than LAD-I and is caused by defects in 
fucosylation of oligosaccharides including PSGL-1 and other selectin 
ligands [22-24]. The binding of P- and E-selectin expressed on 
endothelial cells to leukocyte PSGL-1, CD44 and ESL-1 signals to 
activate the beta2-integrins LFA-1 and Mac-1.This promotes tethering/
rolling and arrest of leukocytes prior to extravasation at sites of 
infection [2]. The gene for GDP-fucose specific transporter (SLC35C1) 
is mutated in LAD-II, affecting either its function and/or its subcellular 
localisation [23]. SLC35C1 knockout mice presented with a condition 
similar to that of LAD-II patients, with symptoms including severe 
growth retardation, elevated postnatal mortality, dilation of lung 
alveoli and hypocellular lymph nodes [25,26].
LAD-III
More recently, a LAD-I variant syndrome now called LAD-III 
was identified. In this disorder, the patients display similar symptoms 
to patients with LAD-I, but also present with a Glanzmann-type 
bleeding disorder and in some cases also with osteopetrosis [27-30]. 
The causative mutations were found to occur in the FERMT3 gene that 
encodes kindlin-3, introducing premature stop codons resulting in a 
non-functioning protein [31-36]. Kindlin-3 is one of three orthologs 
found in humans and has been shown to bind to and regulate beta1-, 
beta2- and beta3-integrin functions [37]. The generation of kindlin-3 
knockout mice were of pivotal importance in the elucidation of the 
molecular defect in LAD-III, and have also aided the understanding of 
how kindlin-3 regulates integrins in different cell types [37]. However, 
much remains to be discovered about the roles of this fundamental 
integrin regulator in different immune cell types and in immune 
functions in vivo, as kindlin-3 knockout mice also suffer from the 
bleeding disorder found in human LAD-III and as a result die soon 
after birth.
Because several classes of integrins are affected by kindlin-3 
deficiency, the symptoms of LAD-III are more complex than those 
of LAD-I. As kindlin-3 regulates beta3-integrin-mediated adhesion 
in platelets, LAD-III patients suffer from a bleeding disorder [31,32]. 
The osteopetrosis is related to deficient osteoclast-mediated bone 
resorption, which is regulated by several integrin subclasses and their 
signalling in these cells [34]. Also, deficiencies in T cell adhesion 
and activation, NK cell activation and erythrocyte shape have been 
described in LAD-III patients [38,39].
Kindlin-3 shares some properties with the well-characterized 
integrin activator talin. Like talin, kindlin-3 contains a FERM motif 
(FERM stands for 4.1, ezrin, radixin, moesin), and appears to be critical 
for integrin adhesion, through its binding to the integrin beta-chain 
cytoplasmic tail. However, kindling binds to a site distinct from that 
of talin. The talin binding site lies at a membrane proximal NXXY 
motif whereas kindlin-3 binds at the membrane-distal NXXY/F motif 
in the integrin beta-chain cytoplasmic domain [40,41]. At present, it 
is unclear whether the binding of either protein excludes or indeed 
promotes that of the other [2,42]. Certainly both are required for beta2-
integrin-mediated adhesion and arrest of leukocytes on endothelium 
under conditions of shear flow [43]. Kindlin-3 is also important for 
outside-in signalling through integrins, perhaps by stabilising the 
adhesive contacts required, for example, under shear flow conditions 
[44]. There is little doubt that there will be much research activity in 
Figure 1: Beta2-integrin functions in the immune system. Beta2-integrins are 
critical to many functions inthe immune system.  Complement receptors 3 and 
4 (Mac-1 and CD11c/CD18) mediate phagocytosis of complement opsonized 
particles, and are important for theclearance of immune complexes and 
apoptotic cells.  Binding of beta2-integrins on T cells to ICAM-1 on dendritic 
cells strengthens thecell-cell interaction and contributes to T cell activation. 
Beta2-integrin outside-in signalling in macrophages dampens TLR signalling 
and inflammatory cytokine production.  The binding of leukocyte integrins to 
ICAM ligands expressed on endothelial cells arrests leukocytes at sites of 
inflammation and precedes extravasation into surrounding tissue. 
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this field in the coming years, leading to an increased understanding of 
the role and regulation of leukocyte beta2-integrins in vitro, in vivo and 
in genetic disorders.
SLE and Mac-1
Interestingly, beta2-integrins have also been linked to a disorder at 
the other end of the immunological disease spectrum. Systemic Lupus 
Erythematosus (SLE) is a type III hypersensitivity (immune complex-
mediated) disorder prevalent in women of child bearing age [45]. It 
is a clinically heterogeneous disease, affecting many organs in the 
body such as the skin, heart, lungs, liver, kidneys, joints and central 
nervous system [46]. This disorder has a strong genetic component, 
and it is more common and more severe in non-European populations. 
Reduced “waste disposal” has been proposed as a disease mechanism 
in lupus. Inefficient phagocytosis by macrophages/neutrophils may 
lead to an accumulation of apoptotic cells and fragments (“cellular 
waste”), which may be taken up by immune cells, such as dendritic 
cells, and lead them to present nuclear antigens to T cells. This may in 
turn contribute to B cell activation and production of autoantibodies 
against nuclear antigens, which lies at the heart of the formation and 
accumulation of immune complexes in this disease [47].
Recently, several genome wide association studies have found an 
association between SLE susceptibility and the ITGAM-ITGAX gene 
region (encoding for CD11b and CD11c integrin chains, respectively) 
[48,49]. Further, the single nucleotide polymorphism (SNP) rs1143679 
has been robustly associated with SLE development in several studies 
[50]. It has also been found to influence the risk of renal disease, discoid 
rash and immunological manifestations in SLE patients [51,52]. The 
rs1143679 SNP occurs within the CD11b coding region and encodes a 
histidine instead of an arginine at position 77 of the CD11b polypeptide. 
Amino acid77 lies in the beta-propeller domain proximal to the ligand 
binding domain in the extracellular region of Mac-1. 
The substitution of R77 withH77 was not predicted to affect ligand 
binding and indeed, studies have shown that the affinity for ligand of 
H77-Mac-1 appears to be unchanged [53,54]. Also, surface expression 
of the variant form is normal. However, it was demonstrated that 
H77-Mac-1 integrin-mediated functions are altered as compared to 
the normal (non-disease associated) R77-Mac-1. In particular, H77-
Mac-1 displays reduced ability to mediate phagocytosis of iC3b-coated 
particles [53,54]. More recently, a study comparing Mac-1-mediated 
phagocytosis in cells from healthy donors expressing either R/H, H/H 
and R/R variants of Mac-1observed reduced phagocytosis in cells 
isolated from the R/H and H/H subjects, although the effect was fairly 
small [55]. Experiments from our laboratory appear to corroborate 
this observation. We report here that R/H heterozygous macrophages 
display slightly reduced Mac-1 mediated phagocytosis (Figure 2), 
though the difference was not statistically significant. Although the 
effect is modest, the deficiency in phagocytosis may contribute to 
SLE development through prolonged inflammation, or may relate 
to inefficient clearance of apoptotic cells and/or immune complexes, 
thereby fuelling the disease.
The ability of the H77-Mac-1 integrin to dampen inflammatory 
cytokine production has also been examined. TLR7/8- or Mac-1-
stimulated cytokine production in freshly isolated polymorphonuclear 
leukocytes was unchanged between the genotypes [55]. However, iC3b-
binding to R77-Mac-1 prior to stimulation of TLR7/8 led to a reduction 
in production of inflammatory cytokines IL-1beta, IL-6 and TNF-
alpha in monocytes. This effect was reduced in the H77 homozygous 
monocytes [54]. In other words, the H77-variant of Mac-1 is not as 
capable as the R77-variant in suppressing cytokine production in 
monocytes.
The effect of the H77 mutation on integrin-mediated adhesion and 
function is not confined to iC3b binding and phagocytosis. Adhesion 
of H77-Mac-1 transfected cells to ICAM-1 was also severely reduced, 
especially under conditions of shear flow (mimicking the conditions in 
blood vessels) [53]. Additionally, H77-Mac-1 homozygous monocyte 
adhesion to ICAM-1was also slightly reduced, although the presence of 
LFA-1 in these cells may have masked somewhat the effect of the H77-
Mac-1 in these assays [54]. In contrast, R/H heterozygous macrophage 
adhesion to ICAM-1 is relatively normal (Figure 2), although the effect 
of this variant on human primary monocyte/neutrophil adhesion to 
ICAM-1 under shear flow conditions has not been examined.
Figure 2: Phagocytosis and adhesion of monocyte derived macrophages 
from individuals homozygous (77R/R) or heterozygous (77R/H) for the Mac-
1 alleles. Monocytes from buffy coats (obtained from the Scottish National 
Blood Transfusion Service, Ninewells Hospital) were isolated and cultured in 
Macrophage specific serum free media (Life technologies) with 10ng/ml GM-
CSF (Peprotech) for 6 days prior to experiments, resulting in differentiation of 
monocytes to macrophages, as analysed by flow cytometry for macrophage 
markers (CD14high, CD11bhigh)(not shown). A-Cell surface expression of 
CD11b and CD18 was examined by flow cytometry using CD11b and CD18 
specific antibodies (Biolegend) and was similar in 77R/H heterozygous cells 
(red) and 77RR cells (blue).  Isotype control is shown in black. B-Phagocytosis 
of iC3b-coated fluorescent beads.Monocyte-derived macrophages from 
individuals homozygous (77R/R, n=17) or heterozygous (77R/H, n=5) were 
challenged with fluorescent beads coated with iC3b or with IgM alone [56] for 
20 min prior to washing and analysis by flow cytometry.  The percentage of 
cells with increased fluorescence due to bead phagocytosis was measured, 
and that solely due to Complement -mediated phagocytosis was calculated 
by subtracting the percentage phagocytosis of IgM coated beads from that 
of iC3b coated beads. C-Monocyte –derived macrophages were analysed in 
static adhesion assays [57] on plates coated with 6 µg/ml human ICAM-1 (R 
and D systems)as described previously [57].  Prior to adhesion cells were 
incubated with control IgG (blue), anti-CD11b (red) or anti-CD18 (green) to 
estimate the separate contributions of beta2-family integrins to cell-adhesion, 
and then stimulated with PdBuor magnesium to activate integrins. D-Adhesion 
of 77R/H heterozygous macrophages (red) and 77R/R macrophages (blue) to 
ICAM-1was examined as above using monocyte-derived macrophages from 
individuals homozygous (77R/R, n=18) or heterozygous (77R/H, n=6) for the 
Mac-1 allele.  No significant differences in adhesion were observed.
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Notably, any effects of the H77 variation on functions mediated 
through Mac-1 binding to ICAM-1 have yet to be examined in ex 
vivo human leukocytes. Mac-1 has been shown to inhibit several 
immunological processes through its binding to ICAM-1 or through its 
effect on signalling, as described earlier, and several of these processes 
may impact on SLE development.The prominent hypothesis is that 
signal transduction through the integrin is compromised in the H77-
Mac-1 variant. However, the exact molecular mechanism involved 
and the signalling pathways affected by this mutation have not been 
elucidated, and studies in this area are eagerly awaited.This hypothesis 
would predict that all possible functions of Mac-1 would be potentially 
compromised. Therefore, although the main contributory effect of 
the H77 variant on SLE may be through reduced Mac-1-mediated 
phagocytic uptake (influencing clearance of immune complexes and 
apoptotic cells), it remains to be seen if other, ICAM-1-dependent 
processes also contribute to the pathology.
Conclusions and Future Prospects
A study of the molecular and immunological mechanisms in 
genetic disorders where beta2-integrin expression or function is 
affected has shed light on the roles of these complicated receptors in 
the immune system. Beta2-integrins are crucial for the recruitment of 
leukocytes into sites of infection or inflammation. Because of this, they 
are of fundamental importance for the generation of, in particular, the 
early innate immune response to bacteria and fungi, as demonstrated 
in human LAD-I and LAD-III syndromes. However, beta2-integrins, 
especially Mac-1, are also important phagocytic receptors, and a 
deficiency in Mac-1-mediated phagocytosis may explain why a 
genetic variant of Mac-1 is associated with SLE. Mac-1 also restricts 
myeloid cell signalling and cytokine production, thereby restricting 
inflammatory responses in vivo. These processes may also be affected 
by the non-functional variant of Mac-1, and therefore be important for 
SLE development. Dysfunctional or absent beta2-integrins therefore 
contribute to immune disease at both ends of the disease spectrum, 
in immunodeficiency and hypersensitivity. Further elucidation of the 
molecular mechanisms involved in regulation of these receptors is 
pivotal for our understanding of the immune system as a whole, and 
may aid in the development of novel therapeutics to immunological 
diseases.
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